Please login to the form below

Not currently logged in
Email:
Password:

BIND Therapeutics appoints Andrew Hirsch as permanent CEO

He had held the role on an interim basis since March

Andrew Hirsch BINDNanomedicine company BIND Therapeutics has appointed Andrew Hirsch as president and chief executive, confirming him in the roles he has held on an interim basis since March.

Prior to that Hirsch, who has now also been elected to BIND's board of directors, served as the Cambridge, Massachusetts-based company's chief operating officer and chief financial officer.

Before joining BIND Hirsch spent almost 10 years at Biogen, rising to VP of corporate strategy and M&A. Commenting on his role at BIND Hirsch said: “I'm excited by the opportunity to continue working with our employees, the senior management team and the Board as we develop therapies with the potential to have a profound impact on the treatment of serious diseases.

“Our nanomedicine platform, one of the most advanced in the industry, enables independent modulation of targeting, cellular trafficking and drug release. Together, these properties enable us to engineer novel therapeutic approaches that can lead to breakthrough therapies.”

The clinical-stage firm is developing targeted and programmable therapeutics called Accurins that it is working on developing into a pipeline of treatments for haematological and solid tumours. Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.

24th June 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Dimitri Azzopardi
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day...
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes....
Interim analysis clinical trials
Assessing the value of interim analyses in clinical trials
Why its important and when its needed...

Infographics